Next Article in Journal
Genome-Wide Identification and Characterization of the UBP Gene Family in Moso Bamboo (Phyllostachys edulis)
Next Article in Special Issue
NK Cell Hyporesponsiveness: More Is Not Always Better
Previous Article in Journal
Small RNA Mobility: Spread of RNA Silencing Effectors and its Effect on Developmental Processes and Stress Adaptation in Plants
Previous Article in Special Issue
Hepatic Tumor Microenvironments and Effects on NK Cell Phenotype and Function
Open AccessReview

Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy

1
Department of Integrated Oncology, Center for Integrated Oncology (CIO), University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany
2
Department of Internal Medicine I, University Hospital Bonn, 53127 Bonn, Germany
3
Department of Internal Medicine II, University Hospital Bonn, 53127 Bonn, Germany
4
Department of Anesthesiology and Postoperative Intensive Care Medicine, University Hospital Bonn, 53127 Bonn, Germany
5
Department of Obstetrics and Gynecology (Senology), University Hospital Bonn, 53127 Bonn, Germany
6
Department of Urology, University Hospital Bonn, 53127 Bonn, Germany
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2019, 20(17), 4307; https://doi.org/10.3390/ijms20174307
Received: 16 June 2019 / Revised: 23 August 2019 / Accepted: 30 August 2019 / Published: 3 September 2019
(This article belongs to the Special Issue Natural Killer and NKT Cells)
Adoptive cellular immunotherapy (ACI) is a promising treatment for a number of cancers. Cytokine-induced killer cells (CIKs) are considered to be major cytotoxic immunologic effector cells. Usually cancer cells are able to suppress antitumor responses by secreting immunosuppressive factors. CIKs have significant antitumor activity and are capable of eradicating tumors with few side effects. They are a very encouraging cell population used against hematological and solid tumors, with an inexpensive expansion protocol which could yield to superior clinical outcome in clinical trials employing adoptive cellular therapy combination. In the last decade, clinical protocols have been modified by enriching lymphocytes with CIK cells. They are a subpopulation of lymphocytes characterized by the expression of CD3+ and CD56+ wich are surface markers common to T lymphocytes and natural killer NK cells. CIK cells are mainly used in two diseases: in hematological patients who suffer relapse after allogeneic transplantation and in patients with hepatic carcinoma after surgical ablation to eliminate residual tumor cells. Dendritic cells DCs could play a pivotal role in enhancing the antitumor efficacy of CIKs. View Full-Text
Keywords: adoptive cellular immunotherapy; Cytokine-induced killer cells; Dendritic cells adoptive cellular immunotherapy; Cytokine-induced killer cells; Dendritic cells
Show Figures

Figure 1

MDPI and ACS Style

Garofano, F.; Gonzalez-Carmona, M.A.; Skowasch, D.; Schmidt-Wolf, R.; Abramian, A.; Hauser, S.; Strassburg, C.P.; Schmidt-Wolf, I.G.H. Clinical Trials with Combination of Cytokine-Induced Killer Cells and Dendritic Cells for Cancer Therapy. Int. J. Mol. Sci. 2019, 20, 4307.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop